# Late-breaking Phase III IgAN data for Vanrafia ALIGN and Fabhalta APPLAUSE-IgAN studies to be presented.124-week Phase I/II zigakibart data evaluating treatment efficacy and safety in IgAN will be featured.

*biotech · news · 2026-05-26 · The Manila Times*

## Key points

- Novartis will present late-breaking Phase III results for Vanrafia (atrasentan) and Fabhalta (iptacopan) in IgAN.
- Fabhalta (iptacopan) achieves near-normal kidney function decline in specific IgA nephropathy patient subgroups.
- 124-week efficacy and safety data for zigakibart in IgA nephropathy will be disclosed at ERA 2026.
- New real-world treatment pattern insights for C3 glomerulopathy patients receiving iptacopan are being presented.

**Companies:** Novartis
**Countries:** Switzerland, United Kingdom

[Read the full story on The Manila Times](https://www.manilatimes.net/2026/05/26/tmt-newswire/globenewswire/new-novartis-data-at-era-2026-advance-scientific-understanding-of-kidney-disease-and-reinforce-portfolio-strength/2351321)

---

Canonical: https://newsio.io/n/727d56bb-95ee-40e5-a617-c7ac974479e3/late-breaking-phase-iii-igan-data-for-vanrafia-align-and-fabhalta-applause-igan
Summarized by Newsio from The Manila Times. https://newsio.io/how-it-works